Here are seven points:
1. The EndoBarrier therapy is designed for glycemic improvement in inadequately controlled, obese, type 2 diabetic subjects on oral anti-diabetic agents.
2. The clinical trial, called the ENDO trial, was terminated early due to seven cases of hepatic abscess.
3. Due to the early termination, only 325 of the planned 500 subjects were randomized into the trial.
4. The ENDO trial results showed the efficacy of the EndoBarrier therapy for the treatment of type 2 diabetes. However, the therapy did not meet the protocol-specified Primary Efficacy Endpoint criterion.
5. With respect to safety, the EndoBarrier therapy did not meet the protocol-specified primary safety endpoint, defined by device-related serious adverse events.
6. The safety failure was largely due to the excess number of hepatic abscess that occurred in subjects implanted with the device.
7. The company plans to submit the final report of the ENDO trial to the FDA in April 2016.
More articles on GI/endoscopy:
3 points on the 2016 Gut Microbiota for Health World Summit
Central Illinois Endoscopy Center performs free colonoscopy for veterans
5 key thoughts from Dr. Brian Hudes on GI physician entrepreneurship
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
